Pfizer confirms patient death in hemophilia drug study

Pfizer confirmed the death of a patient enrolled in a study of its hemophilia drug Hympavzi. The patient suffered a fatal thrombotic stroke after minor surgery. Pfizer said it is gathering information to understand the circumstances. Hympavzi was approved in 2024 for certain hemophilia patients, while broader studies are ongoing.